1 Hematology, Department of Medical Sciences, University of Ferrara, Italy.
2 Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, 'Sapienza' University , Rome , Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) has
dramatically improved thanks to the development of mechanism-driven
agents including drugs that inhibit kinases in the BCR pathway or BCL2.
The treating physician has now the opportunity to decide i) which
patient can be still offered chemoimmunotherapy as salvage treatment,
ii) which patient at relapse is a candidate to receiving, continuous
treatment with ibrutinib, idelalisib and rituximab or venetoclax and
iii) which patient may benefit from a fixed-duration treatment using
the BCL2 antagonist venetoclax in association with rituximab.
A Role for CIT in the R/R Setting?
Treatment Until Progression
|Table 1. Efficacy of recently developed fixed-duration approaches based on novel agents for the treatment of R/R CLL.|
Advantages and Disadvantages of Finite Duration vs Continuous Treatment